The following are some of the stocks that moved up in after-hours trading on Wednesday.
Avalo Therapeutics Inc. (AVTX) has acquired a phase II-ready anti-IL-1ß mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio Inc. AVTX-009 will be explored in the indication of hidradenitis suppurativa and topline results from a planned phase II trial in hidradenitis suppurativa are expected in 2026.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com